SciSparc shares are trading higher after the company received FDA approval to initiate a Phase IIb clinical trial of SCI-110 for the treatment of Tourette syndrome.
Portfolio Pulse from Benzinga Newsdesk
SciSparc shares rose following FDA approval to start a Phase IIb clinical trial for SCI-110, targeting Tourette syndrome.
September 23, 2024 | 12:18 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
SciSparc's stock price increased due to FDA approval for a Phase IIb trial of SCI-110, which is a significant step in developing treatment for Tourette syndrome.
The FDA approval is a critical milestone for SciSparc, indicating progress in their drug development pipeline. This positive regulatory news is likely to boost investor confidence and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100